SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: john.d who wrote (8023)11/15/2001 1:46:21 AM
From: Cal Gary   of 14101
 
Somewhat related, Rheumatoid Arthritis, for anyone other in cyberland that may need this info:
Amgen arthritis drug OK'd
November 14, 2001: 2:11 p.m. ET

FDA approves Kineret, Amgen's new treatment for rheumatoid arthritis.

Amgen
NEW YORK (CNN/Money) - The U.S. Food and Drug Administration, as expected, has approved Amgen Inc.'s new treatment for rheumatoid arthritis, which could help up to 300,000 patients.

Amgen said Wednesday the FDA approved Kineret "for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis in adult patients who have failed one or more disease modifying antirheumatic drugs."

Kineret has a novel mechanism that selectively and directly blocks a certain protein associated with inflammation and arthritis.

An FDA advisory panel voted in favor of approval in August, and the FDA usually follows the advice of the pane.

"Kineret worked for many of my patients," said Dr. Stanley Cohen, a clinical investigator for the drug's trails, in an Amgen statement. "I am impressed with the improvements in my patients' painful and swollen joints."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext